<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361438</url>
  </required_header>
  <id_info>
    <org_study_id>LAL1509</org_study_id>
    <nct_id>NCT01361438</nct_id>
  </id_info>
  <brief_title>De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients</brief_title>
  <acronym>LAL1509</acronym>
  <official_title>A Multicenter Total Therapy Strategy for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients. GIMEMA Protocol LAL1509, EudraCT Number 2010-019119-39</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll adult de novo Ph+ acute lymphoblastic leukemia (ALL) patients (≥18&#xD;
      years, ≤60 years). Induction treatment will consist of 12 weeks of Dasatinib oral&#xD;
      administration (140 mg QD). Patients will initiate treatment with steroids 7 days prior to&#xD;
      starting Dasatinib and will continue up to day 31. Patients will continue treatment with&#xD;
      Dasatinib up to day 84, except for disease progression, intolerable toxicity, or withdrawal&#xD;
      from study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll adult de novo Ph+ acute lymphoblastic leukemia (ALL) patients (≥18&#xD;
      years, ≤60 years). Induction treatment will consist of 12 weeks of Dasatinib oral&#xD;
      administration (140 mg QD). Patients will initiate treatment with steroids 7 days prior to&#xD;
      starting Dasatinib and will continue up to day 31. Patients will continue treatment with&#xD;
      Dasatinib up to day 84, except for disease progression, intolerable toxicity, or withdrawal&#xD;
      from study.&#xD;
&#xD;
      Thereafter:&#xD;
&#xD;
        -  patients in hematological and molecular CR will receive a post-remissional treatment&#xD;
           consisting of Dasatinib alone for a 6 months period&#xD;
&#xD;
        -  patients in hematological CR with persistence of molecular disease will be allografted&#xD;
           or, if not eligible or a donor is not available, treated with 2 cycles of a&#xD;
           Clofarabine-Cyclophosphamide schedule.&#xD;
&#xD;
      After allograft:&#xD;
&#xD;
        -  MRD negative patients (i.e. in CHR and PCR negative) will receive a 6 months Dasatinib&#xD;
           maintenance treatment;&#xD;
&#xD;
        -  MRD positive patients (i.e. in CHR and PCR positive) will receive Dasatinib as&#xD;
           maintenance treatment until relapse or progression.&#xD;
&#xD;
      Patients not transplanted and treated with Clofarabine/Cyclophosphamide will also receive&#xD;
      Dasatinib as maintenance treatment until relapse or progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2011</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of the trial is to estimate the feasibility of a total therapy strategy in de novo adult Ph positive ALL.</measure>
    <time_frame>at 42 months</time_frame>
    <description>The primary endpoint is the rate of patients alive in CHR who have completed the trial treatment according to the therapeutic strategy;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The median value of the minimum of PCR levels achieved in each patient during the Dasatinib treatment within day +85, whenever achieved from the start of the Dasatinib.</measure>
    <time_frame>at 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients who become PCR negative after Dasatinib induction.</measure>
    <time_frame>at 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Out of patients who become PCR negative after induction, the rate of patients who remain persistently negative during maintenance treatment with Dasatinib (without chemotherapy or allogeneic transplant).</measure>
    <time_frame>at 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The median value of the minimum of PCR levels achieved in each patient after an allogeneic transplant or Clofarabine-Cyclophosphamide treatment as consolidation therapy.</measure>
    <time_frame>at 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients alive in CHR who have completed the maintenance program with Dasatinib after an allogeneic transplant or two cycles of Clofarabine-Cyclophosphamide as consolidation therapy.</measure>
    <time_frame>at 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival estimation starting from the date of evaluation of CHR.</measure>
    <time_frame>at 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse estimation starting from the date of evaluation of CHR.</measure>
    <time_frame>at 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival estimation starting from date of inclusion.</measure>
    <time_frame>at 42 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>ALL Ph Positive</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Total therapy approach</intervention_name>
    <description>Total therapy approach</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with de novo Ph+ and/or BCR/ABL+ ALL.&#xD;
&#xD;
          -  Age ≥18 years old ≤60 years.&#xD;
&#xD;
          -  No prior treatment with any anti-leukemic drugs with the exception of steroids for no&#xD;
             more than 14 days (including the 7-day pretreatment already scheduled in the&#xD;
             protocol).&#xD;
&#xD;
          -  WHO performance status ≤2.&#xD;
&#xD;
          -  No evidence of central nervous system (CNS) leukemia.&#xD;
&#xD;
          -  Normal serum level of potassium, total calcium corrected for serum albumin magnesium&#xD;
             and phosphorus, or correctable with supplements.&#xD;
&#xD;
          -  ALT and AST ≤2.5 x ULN or ≤5.0 x ULN if considered due to leukemia.&#xD;
&#xD;
          -  Alkaline phosphatase ≤2.5 x ULN unless considered to leukemia.&#xD;
&#xD;
          -  Serum bilirubin ≤2 x ULN.&#xD;
&#xD;
          -  Serum creatinine ≤3 x ULN.&#xD;
&#xD;
          -  Serum amylase ≤1.5 x ULN and serum lipase ≤1.5 x ULN.&#xD;
&#xD;
          -  Normal cardiac function.&#xD;
&#xD;
          -  Written informed consent prior to any study procedures being performed. In addition,&#xD;
             patients must be thoroughly informed about all aspects of the study, including the&#xD;
             study visit schedule and required evaluations and all regulatory requirements for&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impaired cardiac function, including any one of the following:&#xD;
&#xD;
               -  LVEF &lt;45% as determined by MUGA scan or echocardiogram.&#xD;
&#xD;
               -  Complete left bundle branch block.&#xD;
&#xD;
               -  Use of a cardiac pacemaker.&#xD;
&#xD;
               -  ST depression of &gt;1mm in 2 or more leads and/or T wave inversions in 2 or more&#xD;
                  contiguous leads.&#xD;
&#xD;
               -  Congenital long QT syndrome.&#xD;
&#xD;
               -  History of or presence of significant ventricular or atrial arrhythmia.&#xD;
&#xD;
               -  Clinically significant resting bradycardia (&lt;50 beats per minute).&#xD;
&#xD;
               -  QTc &gt;450 msec on screening ECG (using the QTcF formula).&#xD;
&#xD;
               -  Right bundle branch block plus left anterior hemiblock, bifascicular block.&#xD;
&#xD;
               -  Myocardial infarction within 3 months prior to starting Dasatinib.&#xD;
&#xD;
               -  Angina pectoris.&#xD;
&#xD;
               -  Other clinically significant heart disease (e.g., congestive heart failure,&#xD;
                  uncontrolled hypertension, history of labile hypertension, or history of poor&#xD;
                  compliance with an antihypertensive regimen).&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of Dasatinib (e.g., ulcerative diseases, uncontrolled nausea,&#xD;
             vomiting, diarrhea, malabsorption syndrome, or small bowel resection).&#xD;
&#xD;
          -  Use of therapeutic warfarin.&#xD;
&#xD;
          -  Acute or chronic liver or renal disease considered unrelated to leukemia.&#xD;
&#xD;
          -  Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled&#xD;
             diabetes) that could cause unacceptable safety risks or compromise compliance with the&#xD;
             protocol.&#xD;
&#xD;
          -  Active uncontrolled systemic fungal, bacterial, viral, or other infection (defined as&#xD;
             exhibiting ongoing signs/symptoms related to the infection and without improvement,&#xD;
             despite appropriate antibiotics or other treatment).&#xD;
&#xD;
          -  Treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF,&#xD;
             GMCSF) ≤1 week prior to starting study drug.&#xD;
&#xD;
          -  Patients who are currently receiving treatment with any of the medications listed in&#xD;
             &quot;Appendix H&quot; and the treatment cannot be either discontinued or switched to a&#xD;
             different medication prior to starting study drug. The medications listed in &quot;Appendix&#xD;
             H&quot; have the potential to prolong the QT interval.&#xD;
&#xD;
          -  Patients who have received any antileukemic agents and treatments including steroids.&#xD;
             for more than 14 days including 7 days pretreatment that is part of the protocol.&#xD;
&#xD;
          -  Patients who have received any investigational drug in the last 2 weeks.&#xD;
&#xD;
          -  Patients who have undergone major surgery ≤2 weeks prior to starting study drug or who&#xD;
             have not recovered from side effects of such therapy.&#xD;
&#xD;
          -  Patients who are pregnant or adults of reproductive potential not employing an&#xD;
             effective method of birth control. Women of childbearing potential must have a&#xD;
             negative serum pregnancy test within 48 hrs prior to administration of Dasatinib.&#xD;
             Post-menopausal women must be amenorrhoeic for at least 12 months to be considered of&#xD;
             non-childbearing potential. Male and female patients must agree to employ an effective&#xD;
             barrier method of birth control throughout the study and for up to 3 months following&#xD;
             discontinuation of study drug.&#xD;
&#xD;
          -  Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not&#xD;
             mandatory).&#xD;
&#xD;
          -  Patients with a history of another primary malignancy that is currently clinically&#xD;
             significant or currently requires active intervention.&#xD;
&#xD;
          -  Non compliant to oral medication patients.&#xD;
&#xD;
          -  Significant pleural effusion on baseline chest X-Ray (CXR) or pericardial effusion on&#xD;
             baseline echocardiogram.&#xD;
&#xD;
          -  Use of H2 blockers or proton pump inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Foà, Pr.</last_name>
    <role>Study Chair</role>
    <affiliation>Università Sapienza di Roma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Oncologico Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <state>Potenza</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Nuovo Ospedale &quot;Torrette&quot;</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Area Medica P.O.</name>
      <address>
        <city>Ascoli Piceno</city>
        <zip>63100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera S. G. Moscati</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia 1 - Università degli Studi di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ist.Ematologia e Oncologia Medica L.e A. Seragnoli</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Reg. A. Di Summa</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTMO - Ematologia - Ospedale &quot;Binaghi&quot;</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - P.O. Annunziata - A.O. di Cosenza</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sez.Ematologia e Dip. scienze Biomediche Arcispedale S. Anna</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Ematologia Ospedali Riuniti Foggia - Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Università degli Studi</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale &quot;Santa Maria Goretti&quot;</name>
      <address>
        <city>Latina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Le1 P.O. Vito Fazzi - U.O. di Ematologia</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti &quot;Papardo Piemonte&quot; di Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda &quot; Ca Granda&quot;</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Modenese - Dipartimento di Oncoematologia</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale &quot;A. Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Università degli Studi di Napoli &quot;Federico II&quot; - Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servizio Sanitario Nazionale - Azienda Ospedaliera di Rilievo Nazionale &quot;A. Cardarelli&quot; - Struttura Complessa di Ematologia - Div. TERE</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. D'Arco</name>
      <address>
        <city>Nocera Inferiore</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia con trapianto di midollo - A.U. Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Maddalena Casa di Cura di Alta Specialità Dipartimento Oncologico di III Livello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Div. di Ematologia IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Pisa Dipartimento di Oncologia, dei Trapianti e delle nuove Tecnologie in Medicina - Div. di Ematologia</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O.&quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia - Università Campus Bio-Medico</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umberto I di Roma - Dipartimento di Biotecnologie Cellulari ed Ematologia</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera &quot;Sant' Andrea&quot;-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complesso Ospedaliero S. Giovanni Addolorata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Ospedale S. Camillo</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Tor Vergata</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Eugenio</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Serv. di Ematologia Ist. di Ematologia ed Endocrinologia</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa Ematologia - Azienda Sanitaria Locale BAT1- Presidio Ospedaliero Bisceglie-Trani</name>
      <address>
        <city>Trani</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia - Azienda Ospedaliera - Pia Fondazione di Culto e di Religione Card. G.Panico</name>
      <address>
        <city>Tricase</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario - Clinica Ematologia</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation website</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2011</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

